An N. Cheng
Sendai, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Astrocytic FABP5 drives non-cell-autonomous oligodendrocyte injury in multiple system atrophy by promoting TNF signaling and ferroptotic stress.
Journal: Redox biology
Published: March 23, 2026
Dopamine D2 Receptors, D1/D2 Receptor Heteromers and CaMKII Signaling in the Neurobiology of Drug Addiction.
Journal: Molecular neurobiology
Published: February 03, 2026
Feasibility and considerations of epsin2 as a candidate target for multiple system atrophy treatment.
Journal: Expert opinion on therapeutic targets
Published: October 30, 2023
Editorial: Myelin in white mater function and related diseases.
Journal: Frontiers in molecular neuroscience
Published: August 28, 2023
Pharmacological inhibition of FABP7 by MF 6 counteracts cerebellum dysfunction in an experimental multiple system atrophy mouse model.
Journal: Acta pharmacologica Sinica
Published: March 30, 2023
Amelioration of Nicotine-Induced Conditioned Place Preference Behaviors in Mice by an FABP3 Inhibitor.
Journal: International journal of molecular sciences
Published: March 01, 2023
Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice.
Journal: Journal of pharmacological sciences
Published: November 10, 2022
Role of fatty acid-binding protein 7 and novel therapeutic approach in synucleinopathies
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: November 03, 2022
α-Synuclein decoy peptide protects mice against α-synuclein-induced memory loss.
Journal: CNS neuroscience & therapeutics
Published: October 14, 2022
Epsin2, a novel target for multiple system atrophy therapy via α-synuclein/FABP7 propagation.
Journal: Brain : a journal of neurology
Published: October 06, 2022
Last Updated: 09/26/2026